Does Cosentyx Weaken Vaccine Protection?
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, suppresses parts of the immune system that fight infections. Clinical data shows it reduces vaccine-induced defenses against certain infections, particularly intracellular pathogens like tuberculosis (TB).[1][2]
A phase 3b trial (JUVENTAS) tested response to the live measles-mumps-rubella (MMR) vaccine in adults on stable Cosentyx doses. Only 38% of Cosentyx patients achieved protective measles titers (≥120 mIU/mL) post-vaccination, compared to 58% on placebo. Similar drops occurred for mumps (33% vs. 49%) and rubella (29% vs. 44%). No serious infections followed, but antibody responses were notably blunted.[2]
How Does It Affect Specific Vaccines?
- Live vaccines (e.g., MMR, varicella, yellow fever): Avoid during Cosentyx treatment and for 4-6 weeks after stopping, per FDA labeling. Efficacy drops due to IL-17's role in T-cell immunity.[1][3]
- Inactivated/non-live vaccines (e.g., flu, COVID-19, pneumococcal): Generally safe and recommended before or during treatment. Responses are preserved for most, like influenza (similar seroprotection rates to placebo) and tetanus-diphtheria.[1][4]
- BCG vaccine: Contraindicated; Cosentyx increases disseminated BCG risk.[1]
Real-world studies confirm adequate COVID-19 vaccine responses in Cosentyx users, though slightly lower antibody levels vs. healthy controls.[5]
What Infections Are Patients Worried About?
Patients report higher rates of upper respiratory infections (18-22% vs. 11% placebo) and candida (3-4% vs. <1%). Vaccine defense issues tie into this: weakened IL-17 signaling impairs neutrophil and mucosal defenses against fungi, bacteria, and some viruses.[1][6] TB screening is required before starting, as Cosentyx elevates reactivation risk.[3]
No broad "infection defense collapse," but targeted gaps exist—e.g., poorer pneumococcal response in some biologic users, including IL-17 inhibitors.[4]
Timing and Management Tips
Vaccinate before starting Cosentyx if possible. Post-treatment, wait 4 weeks for live vaccines. Monitor titers if high-risk (e.g., travel). Novartis advises annual flu/pneumococcal shots regardless.[1][3]
| Vaccine Type | Response on Cosentyx | Recommendation |
|--------------|----------------------|----------------|
| Live (MMR, varicella) | Reduced (30-40% protective) | Avoid |
| Inactivated (flu, COVID) | Mostly intact | Proceed |
| TB/BCG | Severely impaired | Screen/avoid |
Comparisons to Other Biologics
Cosentyx's vaccine impact is milder than TNF inhibitors (e.g., Humira, which cuts MMR response to <20%) but similar to IL-23 inhibitors like Tremfya. JAK inhibitors (Xeljanz) show variable hits on live vaccines.[4][7]
| Drug Class | MMR Response Drop | Key Concern |
|------------|-------------------|-------------|
| IL-17 (Cosentyx) | Moderate | Fungal/TB |
| TNF (Humira) | Severe | All infections |
| IL-23 (Tremfya) | Moderate | Similar to Cosentyx |
[1]: FDA Cosentyx Label
[2]: JUVENTAS Trial (Lancet 2021)
[3]: Novartis Prescribing Info
[4]: EULAR Vaccine Guidelines (2023)
[5]: COVID Response Study (Rheumatology 2022)
[6]: Cosentyx Safety Data (JAAD 2020)
[7]: Biologic Comparison Review (Drugs 2022)